Eloxx Pharmaceuticals Future Growth
Future criteria checks 0/6
We currently don't have sufficient analyst coverage to forecast growth and revenue for Eloxx Pharmaceuticals.
Key information
n/a
Earnings growth rate
n/a
EPS growth rate
| Pharmaceuticals earnings growth | 23.9% |
| Revenue growth rate | n/a |
| Future return on equity | n/a |
| Analyst coverage | None |
| Last updated | n/a |
Recent future growth updates
Recent updates
Eloxx says lead asset failed in mid-stage cystic fibrosis trial
Sep 14Eloxx Pharmaceuticals GAAP EPS of -$0.12 in-line
Aug 15Is Eloxx Pharmaceuticals (NASDAQ:ELOX) Using Debt In A Risky Way?
Sep 09
Eloxx Pharmaceuticals EPS misses by $0.06
May 06What Kind Of Investors Own Most Of Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX)?
Feb 17Eloxx secures additional funding from CF Foundation for ELX-02 mid-stage study in cystic fibrosis
Jan 13In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Eloxx Pharmaceuticals has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 9/30/2023 | N/A | -20 | -18 | -18 | N/A |
| 6/30/2023 | N/A | -24 | -22 | -21 | N/A |
| 3/31/2023 | N/A | -31 | -29 | -29 | N/A |
| 12/31/2022 | N/A | -36 | -32 | -32 | N/A |
| 9/30/2022 | N/A | -42 | -36 | -36 | N/A |
| 6/30/2022 | N/A | -44 | -37 | -37 | N/A |
| 3/31/2022 | N/A | -70 | -37 | -37 | N/A |
| 12/31/2021 | N/A | -67 | -35 | -35 | N/A |
| 9/30/2021 | N/A | -61 | -30 | -30 | N/A |
| 6/30/2021 | N/A | -57 | -27 | -27 | N/A |
| 3/31/2021 | N/A | -29 | -24 | -24 | N/A |
| 12/31/2020 | N/A | -35 | -28 | -28 | N/A |
| 9/30/2020 | N/A | -40 | -33 | -33 | N/A |
| 6/30/2020 | N/A | -46 | -39 | -39 | N/A |
| 3/31/2020 | N/A | -53 | -42 | -42 | N/A |
| 12/31/2019 | N/A | -51 | -39 | -39 | N/A |
| 9/30/2019 | N/A | -53 | -39 | -39 | N/A |
| 6/30/2019 | N/A | -52 | -36 | -36 | N/A |
| 3/31/2019 | N/A | -51 | -35 | -35 | N/A |
| 12/31/2018 | N/A | -47 | -32 | -31 | N/A |
| 9/30/2018 | N/A | -45 | -29 | -29 | N/A |
| 6/30/2018 | N/A | -38 | -24 | -24 | N/A |
| 3/31/2018 | N/A | -29 | -19 | -19 | N/A |
| 12/31/2017 | N/A | -24 | -16 | -16 | N/A |
| 9/30/2017 | N/A | -16 | -14 | -14 | N/A |
| 12/31/2016 | N/A | -11 | N/A | -9 | N/A |
| 12/31/2015 | N/A | -7 | N/A | -6 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: Insufficient data to determine if ELOX's forecast earnings growth is above the savings rate (2.6%).
Earnings vs Market: Insufficient data to determine if ELOX's earnings are forecast to grow faster than the US market
High Growth Earnings: Insufficient data to determine if ELOX's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: Insufficient data to determine if ELOX's revenue is forecast to grow faster than the US market.
High Growth Revenue: Insufficient data to determine if ELOX's revenue is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if ELOX's Return on Equity is forecast to be high in 3 years time